= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Coll de la Rubia

MSACL 2018 EU Abstract

Topic: Proteomics

Podium Presentation in the Ether on Thursday at 14:50 (Chair: Yuri van der Burgt)

Exosome-like Vesicles of Uterine Aspirates Permit the Identification of Diagnostic and Stratification Biomarkers of Endometrial Cancer

Eva Coll de la Rubia (Presenter)
Vall Hebron Research Institute

Authors: Irene Campoy (1), Cristian P. Moiola (1), Marc Hirschfeld (2), Jasmin Asberger (2), Silvia Cabrera (3), Xavier Matias-Guiu (4), Eduard Sabidó (5), Antonio Gil-Moreno (1,3), Pierre Thibault (6), Eva Colás (1)
(1) Biomedical Research Group in Gynaecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain (2) Department of Obstetrics and Gynecology, University Medical Center, Albert-Ludwigs-University, Freiburg, Germany (3) Department of Gynecological Oncology, Vall Hebron University Hospital, Barcelona, Spain (4) Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLleida, CIBERONC, Lleida, and Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain (5) Proteomics Unit, Universitat Pompeu Fabra (UPF) and Centre de Regulació Genòmica (CRG), Barcelona, Spain (6) Proteomics and Bioanalytical Mass Spectrometry research unit. IRIC (Institute of Research in Immunology and Cancer)


There is an urgent need to develop non-invasive tests that improve EC detection. In this study, we used exosome-like vesicles isolated from a uterine fluid to identify and verify protein signatures that can differentially diagnose EC subtypes. A discovery phase was performed using a super-SILAC approach on 60 patients (EC type 1, EC type 2, and controls), and a verification phase was done by targeted proteomics (SRM) in 107 patients. A 2-protein signature achieved an AUC=0.935 for EC diagnosis. In addition, we also report a new protein signature that can differentiate type1 versus type2 EC (AUC=0.932). This study has important implications in early detection of EC and in patient stratification.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: